Promising results from early clinical
experience with anti-CD19 CAR T cells in patients with autoimmune
diseases
Optimal CAR construct design contributing to
an acceptable safety profile, and potential for lasting immune
reset are key for treatment adoption
Kyverna is currently recruiting for multiple
KYSA trials where the company's product candidate KYV-101 is used
to treat patients suffering from myasthenia gravis, multiple
sclerosis, and lupus nephritis
EMERYVILLE, Calif., June 10,
2024 /PRNewswire/ -- Kyverna Therapeutics, Inc.
(Kyverna), a patient-centered, clinical-stage biopharmaceutical
company focused on developing cell therapies for patients suffering
from autoimmune diseases, announced today the publication in Nature
Reviews Immunology of a manuscript co-authored with the National
Institutes of Health titled "Chimeric antigen receptor T cell
therapy for autoimmune disease"1.
With more than 30 ongoing sponsored clinical trials and a
growing number of published clinical evidence suggesting the
potential of CAR T-cell therapy approaches for autoimmune
diseases, the manuscript highlights key considerations on optimal
target cell population, CAR construct design, acceptable
toxicities, and potential for lasting immune reset.
"It is quite exciting to see how the learnings from the
development of innovative CAR T-cell approaches for the treatment
of cancer patients are now being applied to the treatment of
patients with autoimmune diseases," said James Kochenderfer, M.D., senior investigator,
clinician, and translational researcher in the Surgery Branch of
the National Cancer Institute, National Health Institutes of Health
in Bethesda, MD. "I look forward
to seeing further progress in this emerging field ultimately
leading towards a potential breakthrough in patient treatment."
"We are very proud of our scientific collaboration with widely
recognized opinion leaders in CAR T-cell therapy," said
Peter Maag, Ph.D., chief executive
officer of Kyverna. "By rapidly advancing an evidence-based science
we may bring potentially long-lasting, treatment-free therapeutic
options to many patients in need."
About KYV-101
KYV-101 is an autologous, fully human CD19 CAR T-cell product
candidate for use in B cell-driven autoimmune diseases. The CAR in
KYV-101 was designed by the National Institutes of Health (NIH) to
improve tolerability and tested in a 20-patient Phase 1 trial in
oncology. Results were published by the NIH in Nature
Medicine2.
KYV-101 is currently being evaluated in sponsored, open-label,
Phase 1/2 and Phase 2 trials of KYV-101 in the United States and Germany across two broad areas of autoimmune
disease: rheumatology and neurology.
With 50 patients treated so far with the CAR in KYV-101 in both
oncological and autoimmune conditions at more than 15 locations in
Europe and the U.S., we believe
that the differentiated properties of KYV-101 are critical for the
potential success of CAR T cells as autoimmune disease
therapies.
KYV-101 is also being evaluated in investigator-initiated trials
for multiple indications in multiple geographies.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc.
(Nasdaq: KYTX) is a patient-centered, clinical-stage
biopharmaceutical company focused on developing cell therapies for
patients suffering from autoimmune diseases.
Our lead CAR T-cell therapy candidate, KYV-101 is advancing
through clinical development with sponsored clinical trials across
two broad areas of autoimmune disease: rheumatology and neurology,
including Phase 2 trials for multiple sclerosis and myasthenia
gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing
multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
Kyverna's pipeline includes next-generation CAR T-cell therapies
in both autologous and allogeneic formats with properties intended
to be well suited for use in B cell-driven autoimmune diseases.
Forward-Looking Statements
Statements in this press
release about future expectations, plans and prospects, as well as
any other statements regarding matters that are not historical
facts, may constitute "forward-looking statements." The words,
without limitation, "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "will," "would" and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these or similar identifying words. Forward-looking statements in
this press release include, without limitation, those related to:
the potential for CAR T-cell therapy to provide lasting immune
reset and to potentially bring long-lasting, treatment free
therapeutic options to many patients in need; Kyverna's goals to
develop certain paradigm-shifting treatment options; Kyverna's
beliefs about the differentiated safety profile and other
properties of KYV-101; and Kyverna's clinical trials. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including: uncertainties related to market conditions, and
other factors discussed in the "Risk Factors" section of Kyverna's
most recent Annual Report on Form 10-K and Quarterly Reports on
Form 10-Q that Kyverna has filed or may subsequently file with the
U.S. Securities and Exchange Commission. Any forward-looking
statements contained in this press release are based on the current
expectations of Kyverna's management team and speak only as of the
date hereof, and Kyverna specifically disclaims any obligation to
update any forward-looking statement, whether as a result of new
information, future events or otherwise.
For more information, please
visit https://kyvernatx.com.
Kyverna Media Contact:
Consort Partners for
Kyverna
kyvernatx@consortpartners.com
1. Chung et al., Nat. Rev. Immunol. (2024).
https://doi.org/10.1038/s41577-024-01035-3
2. Brudno et al., Nat. Med. (2020); 26:270-280.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kyverna-therapeutics-and-national-institutes-of-health-co-author-seminal-review-on-cell-therapy-for-autoimmunity-in-nature-reviews-immunology-302166728.html
SOURCE Kyverna Therapeutics